Literature DB >> 17625428

Risk factors for cholangiocarcinoma.

Tamir Ben-Menachem1.   

Abstract

Cholangiocarcinoma occurs with a varying frequency in different areas of the world. Some of the variations in incidence rates can be explained by the distribution of risk factors in different geographic regions and ethnic groups. Several accepted risk factors for cholangiocarcinoma include infestation with liver flukes, primary sclerosing cholangitis, hepatolithiasis, choledochal cysts, cirrhosis, and infusion of certain chemical agents. Approximately, 90% of patients diagnosed with cholangiocarcinoma do not have a recognized risk factor for the malignancy. The study by Ahrens et al. [16] finds that obesity and gallstones are risk factors for developing extrahepatic cholangiocarcinoma in men patients. Obesity was found to have a 'dose-effect' relationship with the strength of statistical association. No significant association was reported for tobacco or alcohol use, hepatitis, cirrhosis, diabetes, or inflammatory bowel disease. Although the author's definition of extrahepatic cholangiocarcinoma was unusual, the association of obesity with the risk of developing cholangiocarcinoma persisted for all anatomic subsites.

Entities:  

Mesh:

Year:  2007        PMID: 17625428     DOI: 10.1097/MEG.0b013e328224b935

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  34 in total

1.  Clinicopathologic significance of slug expression in human intrahepatic cholangiocarcinoma.

Authors:  Ke-Jun Zhang; Bing-Yuan Zhang; Kun-Peng Zhang; Li-Min Tang; Shi-Song Liu; Dong-Ming Zhu; Dian-Liang Zhang
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

Review 2.  Recent advances in the regulation of cholangiocarcinoma growth.

Authors:  Heather Francis; Gianfranco Alpini; Sharon DeMorrow
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-04-29       Impact factor: 4.052

Review 3.  Perihilar cholangiocarcinoma: Current therapy.

Authors:  Wei Zhang; Lu-Nan Yan
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

4.  NF-κB and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells.

Authors:  Charupong Saengboonmee; Chatchai Phoomak; Suangson Supabphol; Kyle R Covington; Oliver Hampton; Chaisiri Wongkham; Richard A Gibbs; Kazuo Umezawa; Wunchana Seubwai; Marie-Claude Gingras; Sopit Wongkham
Journal:  Life Sci       Date:  2020-10-07       Impact factor: 5.037

5.  Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.

Authors:  Alison L Van Dyke; Meredith S Shiels; Gieira S Jones; Ruth M Pfeiffer; Jessica L Petrick; Jennifer L Beebe-Dimmer; Jill Koshiol
Journal:  Cancer       Date:  2019-01-15       Impact factor: 6.860

6.  Progranulin: a novel regulator of gastrointestinal cancer progression.

Authors:  Sharon Demorrow
Journal:  Transl Gastrointest Cancer       Date:  2013-07

7.  Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M. and Lillian Stratton Basic Research Single-Topic Conference.

Authors:  Alphonse E Sirica; Michael H Nathanson; Gregory J Gores; Nicholas F Larusso
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

8.  Cholangiocarcinoma Risk as Long-term Outcome After Hepatic Resection in the Hepatolithiasis Patients.

Authors:  Hyo Jung Kim; Jae Seon Kim; Sang Jun Suh; Beom Jae Lee; Jong-Jae Park; Hong Sik Lee; Chang Duck Kim; Young-Tae Bak
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

9.  Mesothelin as a potential therapeutic target in human cholangiocarcinoma.

Authors:  Liping Yu; Mingqian Feng; Heungnam Kim; Yen Phung; David E Kleiner; Gregory J Gores; Min Qian; Xin Wei Wang; Mitchell Ho
Journal:  J Cancer       Date:  2010-10-01       Impact factor: 4.207

10.  Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Somsak Likhitrattanapisal; Jaitip Tipanee; Tavan Janvilisri
Journal:  Tumour Biol       Date:  2016-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.